MXPA04004167A - Antagonistas de interleucina-21. - Google Patents

Antagonistas de interleucina-21.

Info

Publication number
MXPA04004167A
MXPA04004167A MXPA04004167A MXPA04004167A MXPA04004167A MX PA04004167 A MXPA04004167 A MX PA04004167A MX PA04004167 A MXPA04004167 A MX PA04004167A MX PA04004167 A MXPA04004167 A MX PA04004167A MX PA04004167 A MXPA04004167 A MX PA04004167A
Authority
MX
Mexico
Prior art keywords
antagonists
helix
mutations
polypeptides
specificity
Prior art date
Application number
MXPA04004167A
Other languages
English (en)
Inventor
W West James
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of MXPA04004167A publication Critical patent/MXPA04004167A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Los polipeptidos, y los polinucleotidos que codifican para ellos, descritos en la presente son antagonistas de IL-21 que se unen con especificidad y exhiben una EC50 que no es detectable en estudios de union a receptores. Estas moleculas tienen mutaciones en la helice D de la molecula de IL-21, y se pueden usar para inhibir la actividad de IL-21 con su receptor cognado.
MXPA04004167A 2001-11-05 2002-10-28 Antagonistas de interleucina-21. MXPA04004167A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33758601P 2001-11-05 2001-11-05
PCT/US2002/034502 WO2003040313A2 (en) 2001-11-05 2002-10-28 Il-21 antagonists

Publications (1)

Publication Number Publication Date
MXPA04004167A true MXPA04004167A (es) 2004-07-08

Family

ID=23321131

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004167A MXPA04004167A (es) 2001-11-05 2002-10-28 Antagonistas de interleucina-21.

Country Status (11)

Country Link
US (3) US6929932B2 (es)
EP (2) EP1451322B1 (es)
JP (2) JP2005508179A (es)
AT (1) ATE444363T1 (es)
AU (1) AU2002336676A1 (es)
CA (1) CA2465156C (es)
DE (1) DE60233888D1 (es)
DK (1) DK1451322T3 (es)
ES (1) ES2334338T3 (es)
MX (1) MXPA04004167A (es)
WO (1) WO2003040313A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
EP1082433A4 (en) * 1998-05-29 2003-01-02 Human Genome Sciences Inc Interleukins 21 and 22
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2004003156A2 (en) 2002-07-01 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Il-21 as a regulator of immunoglobin production
US20070092485A1 (en) * 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
JP4632262B2 (ja) * 2003-02-05 2011-02-16 アイキューム，インク． サンプルの処理
WO2004083249A2 (en) 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
BRPI0408523A (pt) * 2003-03-21 2006-03-21 Wyeth Corp métodos para melhorar um sintoma de esclerose múltipla em um indivìduo, para melhorar esclerose múltipla em um indivìduo mamìfero, para modular uma deficiência de il-10, ou um distúrbio associado com uma deficiência de il-10 em um indivìduo mamìfero, para tratar ou prevenir um distúrbio imunológico em um indivìduo mamìfero e para avaliar o tratamento de esclerose múltipla em um indivìduo mamìfero, composição farmacêutica, e, artigo de manufatura
EP1641422A4 (en) * 2003-06-19 2007-08-22 Centocor Inc ANALOGUES OF INTERLEUKINE-21
US20060228331A1 (en) * 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP1673387B1 (en) * 2003-10-10 2010-09-15 Novo Nordisk A/S Il-21 derivatives
EP2641611A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
ATE474915T1 (de) * 2003-11-19 2010-08-15 Us Gov Health & Human Serv Verfahren zur induktion der entwicklung und terminalen differenzierung von gedächtnis-b- zellen
EP1708737A2 (en) * 2004-01-15 2006-10-11 Novo Nordisk A/S Use of interleukin-21 for the treatment of autoimmune diseases and allograft rejection
MXPA06013483A (es) * 2004-05-19 2007-01-23 Wyeth Corp Modulacion de produccion de inmunoglobulina y trastornos atopicos.
EP1612892B1 (en) * 2004-06-30 2008-03-19 Tyco Electronics Nederland B.V. Connector for electronic components
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
BRPI0609079A2 (pt) * 2005-04-18 2010-11-16 Novo Nordisk As peptìdeo, composição farmacêutica, método para o tratamento de cáncer, uso de um peptìdeo construto de ácido nucleico, vetor, hospedeiro, e, anticorpo
KR20080019025A (ko) * 2005-06-06 2008-02-29 노보 노르디스크 에이/에스 안정화된 ｉｌ-21 조성물
PT1963369E (pt) * 2005-11-28 2013-05-28 Zymogenetics Inc Antagonistas de il-21
US20080003564A1 (en) * 2006-02-14 2008-01-03 Iquum, Inc. Sample processing
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
CA2671665A1 (en) 2006-12-21 2008-06-26 Novo-Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
KR100902340B1 (ko) * 2007-08-02 2009-06-12 한국생명공학연구원 Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
KR101591316B1 (ko) 2007-12-07 2016-02-05 지모제넥틱스, 인코포레이티드 항-사람 ｉｌ-21 단클론성 항체
JP2011509676A (ja) 2008-01-18 2011-03-31 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ヒトＴｈ１７細胞の選択的分化、同定および調節
PE20100141A1 (es) * 2008-05-23 2010-02-22 Wyeth Corp Proteina de union al receptor de interleuquina 21
AU2009248812A1 (en) * 2008-05-23 2009-11-26 Wyeth Llc Methods of treatment utilizing binding proteins of the interleukin-21 receptor
EP3241910B1 (en) 2008-10-08 2020-01-08 Cambridge Enterprise Limited Methods for diagnosis and treatment of autoimmune disease secondary to multiple sclerosis
US20120107267A1 (en) 2009-03-11 2012-05-03 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
EP2596023A4 (en) * 2010-07-20 2014-03-05 Beth Israel Hospital COMPOSITIONS AND METHODS COMPRISING ANTAGONISTS OF IL-6 AND IL-21
JP6395379B2 (ja) 2011-01-18 2018-09-26 バイオニズ リミテッド ライアビリティー カンパニー γｃサイトカイン活性を調節するための組成物および方法
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
US20180036404A1 (en) 2015-03-02 2018-02-08 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
PT3359556T (pt) 2015-10-09 2021-08-30 Bioniz Llc Modulação da atividade de citocinas gama-c
CN117838729A (zh) 2017-04-13 2024-04-09 森迪生物科学公司 组合癌症免疫疗法
TN2020000015A1 (en) 2017-08-03 2021-10-04 Amgen Inc Interleukin-21 muteins and methods of treatment
JP2019122373A (ja) 2018-01-12 2019-07-25 アムジエン・インコーポレーテツド 抗ｐｄ−１抗体及び治療方法
EP3866813A4 (en) 2018-10-17 2022-08-03 Senti Biosciences, Inc. COMBINATORY CANCER IMMUNOTHERAPY
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK368882A (da) 1981-08-25 1983-02-26 Alan John Kingsman Expessions vektorer
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
DE3578435D1 (de) 1984-12-06 1990-08-02 Labofina Sa Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
ES2092468T3 (es) 1988-01-22 1996-12-01 Zymogenetics Inc Metodos para producir analogos de receptores secretados.
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
JPH08502646A (ja) 1992-09-14 1996-03-26 ファイザー・インコーポレイテッド 不死化細胞およびその使用
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
AU1158297A (en) 1995-11-09 1997-05-29 Zymogenetics Inc. Production of gad65 in methylotrophic yeast
AU718510B2 (en) 1996-07-17 2000-04-13 Zymogenetics Inc. Transformation of pichia methanolica
JP2002514049A (ja) 1996-07-17 2002-05-14 ザイモジェネティクス，インコーポレイティド ピヒア・メタノリカの栄養要求性突然変異体の製造
CA2366921C (en) * 1999-03-09 2013-12-17 Zymogenetics, Inc. Novel cytokine zalpha11 ligand
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2003087320A2 (en) 2002-04-09 2003-10-23 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
US9418201B1 (en) 2015-11-19 2016-08-16 International Business Machines Corporation Integration of functional analysis and common path pessimism removal in static timing analysis

Also Published As

Publication number Publication date
EP1451322B1 (en) 2009-09-30
CA2465156C (en) 2011-10-18
EP1451322A2 (en) 2004-09-01
US7410780B2 (en) 2008-08-12
ATE444363T1 (de) 2009-10-15
CA2465156A1 (en) 2003-05-15
DE60233888D1 (de) 2009-11-12
US7186805B2 (en) 2007-03-06
EP1451322A4 (en) 2005-02-02
US6929932B2 (en) 2005-08-16
EP2130919A1 (en) 2009-12-09
ES2334338T3 (es) 2010-03-09
US20070166796A1 (en) 2007-07-19
DK1451322T3 (da) 2010-02-01
US20050244930A1 (en) 2005-11-03
US20030134390A1 (en) 2003-07-17
JP2010207238A (ja) 2010-09-24
WO2003040313A2 (en) 2003-05-15
JP2005508179A (ja) 2005-03-31
AU2002336676A1 (en) 2003-05-19
WO2003040313A3 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
MXPA04004167A (es) Antagonistas de interleucina-21.
WO2005077981A3 (en) Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
YU92503A (sh) Taci-imunoglobulinski fuzioni proteini
WO2002066516A3 (en) Antibodies that bind both bcma and taci
ATE451460T1 (de) Antikörpermoleküle mit spezifizität für menschlichen tumornekrosefaktor-alpha, und deren verwendung
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
DE60138927D1 (de) Menschlicher rezeptor für tumor necrosis factor
ATE287862T1 (de) Leitende zementzusammensetzung
HUP0102005A2 (hu) CD23 elleni antitestek, ezek származékai, és gyógyászati alkalmazásuk
PL358215A1 (en) Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
MX2008000230A (es) Proteinas de enlace il-6.
ZA200605721B (en) The glucagon-like peptide-1 receptor agonists, the preparation and the use of the same
IL157800A0 (en) Il-18 mutants, their production and use
AU9291801A (en) Isolated nucleic acid molecules which encode a soluble il-tif/il-22 receptor or binding protein which binds to il-tif/il-22, and uses thereof
BR0212740B1 (pt) material pulverizado e material cerÂmico fabricado a partir do mesmo.
WO2003018798A3 (en) G-protein coupled receptor and dna sequences thereof
IS6874A (is) 3,7-díasabísýkló[3.3.0]oktön og notkun þeirra í meðhöndlun á hjartsláttarglöpum
WO2003023012A3 (en) Crystal structure of interleukin-22 and uses thereof
WO2002002630A3 (en) Hcn polypeptides and polynucleotides and their use in therapy
IL175646A0 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
WO2006026355A3 (en) Relaxin-chimeric polypeptides and their preparation and use
AU7048901A (en) Edg8 receptor, its preparation and use
AU2002340830A1 (en) Peptides that bind to dna and inhibit dna replication, and methods of use
RU2006139363A (ru) Сырьевая смесь
JP2004511237A5 (es)

Legal Events

Date Code Title Description
FG Grant or registration